Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy 10x Genomics stock | 163.7

Own 10x Genomics stock in just a few minutes.

Posted

Fact checked

10x Genomics, Inc is a health information services business based in the US. 10x Genomics shares (TXG) are listed on the NASDAQ and all prices are listed in US Dollars. 10x Genomics employs 713 staff and has a trailing 12-month revenue of around USD$251.3 million.

How to buy shares in 10x Genomics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for 10x Genomics. Find the stock by name or ticker symbol: TXG. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until 10x Genomics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$163.7, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of 10x Genomics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of 10x Genomics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted 10x Genomics's share price?

Since the stock market crash in March caused by coronavirus, 10x Genomics's share price has had significant positive movement.

Its last market close was USD$163.7, which is 49.91% up on its pre-crash value of USD$82 and 235.59% up on the lowest point reached during the March crash when the shares fell as low as USD$48.78.

If you had bought USD$1,000 worth of 10x Genomics shares at the start of February 2020, those shares would have been worth USD$549.74 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,745.04.

10x Genomics share price

Use our graph to track the performance of TXG stocks over time.

10x Genomics shares at a glance

Information last updated 2020-10-16.
Latest market closeUSD$163.7
52-week rangeUSD$48.78 - USD$165.6
50-day moving average USD$126.8317
200-day moving average USD$95.4704
Wall St. target priceUSD$130
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-7.271

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks
N/A
0%
A free way to invest in stocks, ETFs and crypto.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Tastyworks
$0
Stocks, Options, ETFs, Futures
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy 10x Genomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

10x Genomics price performance over time

Historical closes compared with the close of $163.7 from 2020-10-16

1 week (2020-10-15) 1.08%
1 month (2020-09-22) 33.50%
3 months (2020-07-22) 73.03%
6 months (2020-04-22) 115.39%
1 year (2019-10-22) 199.65%
2 years (2018-10-18) N/A
3 years (2017-10-18) N/A
5 years (2015-10-18) N/A

Is 10x Genomics under- or over-valued?

Valuing 10x Genomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of 10x Genomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

10x Genomics's EBITDA

10x Genomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$10.1 million.

The EBITDA is a measure of a 10x Genomics's overall financial performance and is widely used to measure a its profitability.

10x Genomics financials

Revenue TTM USD$251.3 million
Gross profit TTM USD$214.1 million
Return on assets TTM -9.13%
Return on equity TTM -38.39%
Profit margin -31.06%
Book value $4.385
Market capitalisation USD$17.3 billion

TTM: trailing 12 months

Shorting 10x Genomics shares

There are currently 1.9 million 10x Genomics shares held short by investors – that's known as 10x Genomics's "short interest". This figure is 27.6% up from 1.5 million last month.

There are a few different ways that this level of interest in shorting 10x Genomics shares can be evaluated.

10x Genomics's "short interest ratio" (SIR)

10x Genomics's "short interest ratio" (SIR) is the quantity of 10x Genomics shares currently shorted divided by the average quantity of 10x Genomics shares traded daily (recently around 1.0 million). 10x Genomics's SIR currently stands at 1.82. In other words for every 100,000 10x Genomics shares traded daily on the market, roughly 1820 shares are currently held short.

However 10x Genomics's short interest can also be evaluated against the total number of 10x Genomics shares, or, against the total number of tradable 10x Genomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case 10x Genomics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 10x Genomics shares in existence, roughly 20 shares are currently held short) or 0.0253% of the tradable shares (for every 100,000 tradable 10x Genomics shares, roughly 25 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against 10x Genomics.

Find out more about how you can short 10x Genomics stock.

10x Genomics share dividends

We're not expecting 10x Genomics to pay a dividend over the next 12 months.

Have 10x Genomics's shares ever split?

10x Genomics's shares were split on a 1:2 basis on 17 July 2006. So if you had owned 2 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 10x Genomics shares – just the quantity. However, indirectly, the new 100% higher share price could have impacted the market appetite for 10x Genomics shares which in turn could have impacted 10x Genomics's share price.

10x Genomics overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.

Frequently asked questions

More guides on finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site